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Available online 2 March 2018Dyslipidemia, the disorder of lipoprotein metabolism resulting in high lipid proﬁle, is an important modiﬁable
risk factor for coronary heart diseases. It is associated with more than four million worldwide deaths per year.
Half of the children with dyslipidemia have hyperlipidemia during adulthood, and its prediction and screening
are thus critical. We designed a new dyslipidemia diagnosis system. The sample size of 725 subjects (age
14.66± 2.61 years; 48% male; dyslipidemia prevalence of 42%) was selected by multistage random cluster sam-
pling in Iran. Single nucleotide polymorphisms (rs1801177, rs708272, rs320, rs328, rs2066718, rs2230808,
rs5880, rs5128, rs2893157, rs662799, and Apolipoprotein-E2/E3/E4), and anthropometric, life-style attributes,
and family history of diseases were analyzed. A framework for classifying mixed-type data in imbalanced
datasetswas proposed. It included internal featuremapping and selection, re-sampling, optimized groupmethod
of data handling using convex and stochastic optimizations, a new cost function for imbalanced data and an
internal validation. Its performancewas assessed using hold-out and 4-foldcross-validation. Four other classiﬁers
namely as supported vector machines, decision tree, and multilayer perceptron neural network and multiple
logistic regression were also used. The average sensitivity, speciﬁcity, precision and accuracy of the proposed
system were 93%, 94%, 94% and 92%, respectively in cross validation. It signiﬁcantly outperformed the other
classiﬁers and also showed excellent agreement and high correlation with the gold standard. A non-invasive
economical version of the algorithm was also implemented suitable for low- and middle-income countries. It
is thus a promising new tool for the prediction of dyslipidemia.
© 2018 Marateb et al.. Published by Elsevier B.V. on behalf of theResearchNetwork of Computational and Structural
Biotechnology. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).Keywords:
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Strengthening the capacity of the entire countries, for early warning,
and health risk reduction is one of the targets of the Sustainableics and Epidemiology, Health
n.
sourian).
.V. on behalf of the Research NetworkDevelopment Goal (SDG) #3. Non-communicable diseases (NCDs)
have adverse human, social and economic consequences in all societies.
Also, the ﬁrst global NCD Action Plan is “A 25% relative reduction in the
overall mortality from cardiovascular diseases, cancer, diabetes, or
chronic respiratory diseases” [1]. Coronary heart diseases (CHDs), are
the number 1 source of death and disability in countries including Iran
[1,2]. Dyslipidemia, the disorder of lipoprotein metabolism resulting in
high lipid proﬁle, is a major risk factor of CHD [3]. It is related to moreof Computational and Structural Biotechnology. This is an open access article under the CC
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of dyslipidemia is thus important in targeting SDG #3 and NCD Action
Plan #1.
Metabolic risk factors including dyslipidemia are the most important
determinants of emerging NCDsworldwide [5,6]. Dyslipidemia is, in fact,
an important modiﬁable risk factor for CHD [7]. Although signiﬁcant ad-
verse health outcomes in childhood are not associated with dyslipid-
emia, it was shown in the literature that there is a link between
childhood dyslipidemia and occurrence of atherosclerosis and its
follow-up in adulthood [8,9]. Not only 40–55% of children with dyslipid-
emiawill have hyperlipidemia during adulthood [10], but also subclinical
atherosclerotic abnormalities, resulting in cardiovascular disease (CVD)
events, occur in childhood [11]. Prediction and screening dyslipidemia,
an important CVD risk factor, in children and adolescents is thus critical
[12].
Some studies were performed in the literature to assess the genetic
risk for dyslipidemia [13,14]. In such studies, statistically signiﬁcant
dyslipidemia predictors were identiﬁed, and no actual prediction (or
classiﬁcation) was performed. CAD (Computer-aided diagnosis), on
the other hand, could use risk factors and predict if a subject is at high
risk or not. CAD, which is using data mining to interpret medical
information, could improve the diagnosis accuracy [15]. CAD is in fact
used as a second opinion by the physicians to make the ﬁnal diagnosis
or prognosis decision [16–18].
Two methods were proposed in the literature to predict dyslipid-
emia in adults [19,20]. Wang et al. [19] analyzed 8914 subjects aged
35–78 years (with the prevalence of dyslipidemia about 46%). The
predictors' age, gender, occupation, education, marital status, physical
activity, individual income, waist circumference, smoking, family
history of dyslipidemia, and diet were used to predict dyslipidemia
(High TC, or TG or low HDL-C [21]). Artiﬁcial neural network (ANN)
and Multiple Logistic Regression (MLR) models were used and the
sensitivity, speciﬁcity, and precision of 90%, 77%, and 76%were obtained
in the hold-out (75%) internal validation.
Costanza and Paccaud [20], analyzed 2549 subjects aged 35–64
years (the prevalence of dyslipidemia about 43%). The predictors
waist-to-hip circumference ratio (WHR), body mass index (BMI),
gender, age, current cigarette Smoking, and high blood pressure
were used and dyslipidemia (total serum cholesterol to high-
density lipoprotein cholesterol (TC/HDL-C) ratio ≥5.0) was pre-
dicted using different data mining methods, namely as the linear
and logistic regressions, regression and classiﬁcation trees. The sen-
sitivity, speciﬁcity, and precision of 70%, 77%, and 69% were ob-
tained in the hold-out external validation.
Although the prediction methods proposed in [19,20], are sim-
ple and effective and thus worthwhile for the identiﬁcation of
high risk people for having dyslipidemia based on the demographic,
dietary and life-style, and anthropometric data, an optimal predic-
tion is still required. Genome-based prediction of diseases has
been recently focused in bioinformatics [22]. Identifying genetic
mutations could assist in choosing optimal patient treatment. In
fact, a lot of methods exist to reveal such mutations, including
next-generation sequencing and future commercially available
kits [23]. Moreover, in reliable clinical systems, critical criteria re-
garding statistical errors, precision, and DOR (Diagnosis Odds
Ratio) must be met [24]. Moreover, considering ethnic differences
in life-style, environmental factors and genetic background, exam-
ining gene polymorphisms associated with dyslipidemia in each
ethnic group is important [13].
The purpose of our work is thus to design an accurate and reliable
system for the prediction of dyslipidemia using gene mutations, family
history of diseases and anthropometric indicators in a nationally-
representative sample of the pediatric population in the Middle East
and North Africa (MENA). To the best of our knowledge, this is the ﬁrst
study of its kind for genome-based dyslipidemia prediction using data
mining.2. Material and methods
2.1. Study population
The third study of a school-based surveillance system known as
the childhood and adolescence surveillance and prevention of
Adult Noncommunicable disease (CASPIAN) was conducted in Iran
as the national survey of school students with high-risk behaviors
(2009–2010) [25]. The description of the CASPIAN-III study was pro-
vided elsewhere in details [25]. Here, it is brieﬂy described.
Among the youngsters, long-term changes in disease patterns are
following rapid modiﬁcations in lifestyle, nutrition, and physical
activity. Iranian youths are experiencing such lifestyle changes, making
them prone to risk factors of chronic diseases such as NCDs. Surveilling
such factors is important for long-term national planning based on
monitoring NCD-related risk factors from childhood to adulthood. A
school-based surveillance system entitled as CASPIAN Studywas imple-
mented in IRAN from 2003–2004. The surveys have been repeated
every 2 years, with blood sampling for biochemical factors every 4
years.
This study was performed among 5570 students, sampled from 27
provinces of Iran. The entire students and their parents gave informed
consent to the experimental procedure. It was approved by Isfahan
University of Medical Sciences Panel on Medical Human Subjects and
conformed to the Declaration of Helsinki.
According to the US National Institutes of Health Heart, Lung, and
Blood Institute (NHLBI) guideline, which is one the acceptable criteria,
dyslipidemia was deﬁned for children and Adolescents (age ≤ 19
years) as having at least one of the following: TC (total cholesterol)
≥5.17 mmol/L (≥200 mg/dL), LDL-C (low-density lipoprotein choles-
terol) ≥3.36 mmol/L (≥130 mg/dL), HDL-C (high-density lipoprotein
cholesterol) levels b1.04 mmol/L (b40mg/dL), TG (triglyceride) ≥1.13
mmol/L (≥100 mg/dL) when age is between zero and nine years and
TG ≥1.47 mmol/L (≥130 mg/dL) when age is between 10 and 19 years,
and ﬁnally non-HDL-C (subtracting HDL-C from TC) ≥3.75 mmol/L
(≥145 mg/dL) [7,26].
We randomly selected 725 frozen whole blood samples for genome
analysis from children and adolescents (48% male, 42% prevalence of
dyslipidemia) taken from CASPIAN-III study. Such a sample size was es-
timated based on the sample-size estimation method proposed by
Hajian-Tilaki [27]. Total required sample size (N) could be estimated
based on the target sensitivity (See) and Speciﬁcity (Spe) using Eq.(1):
N ¼ max
z2α=2  See  1−Seeð Þ
d2  Prev
;
z2α=2  Spe  1−Speð Þ
d2  1− Prevð Þ
 !
ð1Þ
whereα is the signiﬁcance level, Prev is the prevalence of the disease in
the population and d is the precision of estimate (i.e.,the maximum
marginal error). The number of subjects in the case (ncase) and control
(ncontrols) categories could be then estimated using Eq.(2):
ncontrols ¼ N  1− Prevð Þ; ncase ¼ N−ncontrols ð2Þ
The parameters See and Spe were set to 70% and 77%, respectively
based on the literature [20]. The prevalence of dyslipidemia in Iranian
population was hypothesized as about 42% [6,28] and parameters α
and d were both set to 0.05 [29]. Thus, the sample size of 725
(ncontrols = 418, ncase = 307), sufﬁced.
2.2. Procedure and measurements
2.2.1. DNA extraction
Single nucleotide polymorphisms (SNPs) of lipoprotein lipase LPL
(D9N [rs1801177]), cholesteryl ester transfer protein CETP (TaqIB
[rs708272]) [30], LPL (HindIII [rs320]), LPL (S447X [rs328]) [31], ATP-
binding cassette transporter-1 ABCA1 (V771M [rs2066718]), ABCA1
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tein C-3 APOC3 (SstI [rs5128]) [35], apolipoprotein A-1 APOA1 (MspI
[rs2893157]) [36], apolipoprotein A-5 APOA5 (C-1131T [rs662799])
[37] and apolipoprotein-E ApoE genes [38,39], appearing to relate to
lipid proﬁle disorders and (or) cardiovascular diseases, were investi-
gated [3,40].
Subjects' peripheral blood was analyzed using the QIAamp DNA
Blood Mini kit (Qiagen, Germany) and DNA was extracted following
the manufacturer's protocol [41]. Corbett rotor-gene 6000 instruments
(Corbett Research Pty Ltd, Sydney Australia) were used for Real-time
PCR and high- resolution melt analysis [42]. The details of later analysis
were mentioned in the Supplementary material S1.
Alleles of the genotypeswere analyzed. Typically, only two out of the
four possible nucleotides occur, and each sample contains a pair of every
autosome. Alternatively, the carrier and non-carrier genes were
represented as a binary variable for each genotype. For example, for
the SNP rs320, nucleotide pairs GG, and TG/GT with the minority
nucleotide G were considered as 'carrier' while the TT pair was set to
'non-carrier'. Thus, two feature sets (nucleotide pairs, and carrier/non-
carriervariables) were considered for further analysis.2.2.2. Other analyzed features
The Anthropometric information was recorded by a team of trained
health care professionals and the examinations were conducted under
standard protocol by using calibrated instruments. Weight was mea-
sured to the nearest 200g in barefoot and lightly dressed condition.
BMI was calculated as weight (kg) divided by height squared (m2).
The parameter weight circumference (WC) was measured using a
non-elastic tape to the nearest 0.2 cm at the end of expiration at the
midpoint between the top of iliac crest and the lowest rib in standing
position [25].
The anthropometric and life-style attributes such as age, sex, hyper-
tension (either high systolic blood pressure (SBP) (≥90th percentile for
age, sex and height) or high diastolic blood pressure (DBP) (≥90th
percentile for age, sex and height) [43]), abdominal obesity (deﬁned as
waist-to-height ratio (WHtR) equal or more than 0.5 [44]), BMI
categories (underweight, normal, overweight and obese deﬁned using
WHO growth curves [45] ) and physical activity (low, moderate, and
severe categories [46]), as well as the family history of diabetes, obesity,
CVD, cancer, andbirthweight (b2500 g (low), 2500 g–4000 g (medium),
and N4000 g (high) categories) were also included.2.3. The proposed diagnosis system
2.3.1. Pre-processing
The dataset was split into the estimation, validation (overall known
as the training set) and test sets (40%, 10%, and 50% respectively in a
hold-out validation setting). The input variables were grouped based
on their interval or categorical measurement scales [47]. The categorical
group consisted of nominal (such as sex) and ordinal (such as birth
order) variables. The interval features were then transferred using
robust Z-score measure [48,49]. In this transformation, the median
and MAD (median absolute deviation) of each feature was estimated,
and the median was then reduced from each feature and then normal-
ized by the MAD value. Such features were then normalized between
zero and one for further processing.
For each categorical feature, the indicator variable was estimated. It
takes the value 0 or 1 to indicate the absence or presence of each cate-
gory. Logit transformation was performed on each indicator variable
whose intercept and slope parameters were estimated usingmaximum
Likelihood Estimating (MLE) on the training set [50]. Thus, each indica-
tor variable was expressed as a continuous value between zero and one.
Such processed features are entitled as "predictors" from now on. The
number of predictors was Np.2.3.2. Optimized inductive learning
Group Method of Data Handling (GMDH), ﬁrst proposed by
Ivakhnenko [51,52], has been applied in many areas for data mining
[53]. Inductive GMDH algorithms ﬁnd interactions in data, select an
optimal network structure and thus improve the performance of
current algorithms [54]. Hereweproposed anoptimizedGMDHmethod
to predict dyslipidemia using mixed-type data.
Feature selection was performed by iteratively estimating their
weights based on their capability to discriminate between neighboring
patterns in the framework of the Expectation-Maximization algorithm
using I-RELIEF algorithm [55]. Moreover, the parallel selective sampling
(PSS) method was used to select data from the majority class as to
reduce the problems in the imbalanced datasets [56].
Multilayered induction for the gradual increase of complexity was
performed using different layers. Instead of the ﬁxed regression polyno-
mial, the nonlinear regressionmatrix (X)was formedbetween anypairs
(i,j) of predictors at the ﬁrst layer that has Nn nonlinear regression
functions:
XNnN1 ¼
a1  ones 1;N1ð Þ
a2  1þ x i; :ð Þð Þa3
a4  x j; :ð Þa5
a6  sin a7  x i; :ð Þ þ a8  x j; :ð Þð Þ
a9  x i; :ð Þ⊙ 1þ x j; :ð Þð Þa10
a11  log2 1þ 1þ x i; :ð Þj ja12
 
a13  log2 1þ 1þ x j; :ð Þj ja14
 
…
2
66666666664
3
77777777775
ð3Þ
where ⊙ is the element-by-element multiplication, ai is the regression
coefﬁcients and N1 is the number of samples in the training set. If we
ﬁx the regression coefﬁcients, the Regularized Least Squares (RLS)
solution to XT ×W≈ B (B is a column vector with the class label of the
analyzed samples) could be estimated as below:
WNn1 ¼ X  XT þ λ INnNn
 −1
 X  B ð4Þ
where λ is the regularization parameter (set to 0.1 in our study), I is the
identity matrix, and T is thematrix transpose operator. It could be easily
shown that the optimal solution is the global minimum point of the RLS
optimization [57]. In principle, it is possible to tune polynomial regres-
sion coefﬁcients using a stochastic optimization [58]. Instead, we tune
the regression coefﬁcients used in the matrix X, using Particle Swarm
Optimization (PSO). PSO is a meta-heuristicspopulation-based method
inspired by ﬂocking birds [59]. The topology and the internal parame-
ters of PSO were the same as Mohebian et al. [15] except that the max-
imum number of iterations was set to 10 and the PSO ﬁtness function
was deﬁned differently. At each PSO iteration, the random regression
coefﬁcients are used to calculate the matrix X for a predictor pair.
Then, the parameter W is estimated on the training set. To avoid over-
ﬁtting, the estimated weightW is used on the validation set to estimate
the output of the analyzed pair in the validation set. The cut-off of 0.5
was then used to estimate the parameters of signal detection theory
such as True Positive (TP), True Negative (TN), False Positive (FP) and
False Negative (FN). Then, parameters Sensitivity (¼ TPTPþFN), Speciﬁcity
(¼ TNTNþFP) and Precision (¼ TPTPþFP) are estimated, and their average is
used as the ﬁtness function. The PSO method usually converged at few
iterations due to the internal RLS optimization.
The selection pressure of the network was set to 0.7, in our study.
Thus, 70% of the best pairswere selected for each layer. The approximat-
ing function of each selected pair was used as new features at the next
layer [54]. The number of layers was estimated based on the required
number of interactions. In a case of Ni interval features and Nd indicator
variables, it was hypothesized as 1 + round(log2(Ni+ Nd)). At the last
layer, the best approximation function was used as the output of the
classiﬁcation system. the overall structure of the proposed prediction
system was shown in the Supplementary material S2.
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In our study, other classiﬁcation methods namely as multilayer
perceptron (MLP), MLR and decision tree (DT), as proposed in other
studies [19,20], were used for comparison. Supported vector machines
(SVM)was also used for comparison.MLP, a feed-forward artiﬁcial neu-
ral network (ANN) model mapping sets of inputs onto a set of outputs
[60],with one hidden layerwith ten neurons and the sigmoid activation
function [61] was used. SVM, constructing a hyper plane in a high-
dimensional space [62], with the radial basis function (RBF) kernels
were used. The soft-margin parameter and the radius of the RBF kernel
were tuned using the method proposed by Wu and Wang [63]. DT,
building classiﬁcation models in the form of a tree structure [64], uses
entropy to calculate the homogeneity of samples to build the tree. The
statistical classiﬁer C4.5 with pruning (i.e., removing redundant sub-
trees) was used in our study [65]. The best splitting attribute is deter-
mined at each node. MLR uses the linear regression model with the
Logit link function for the prediction.
After ﬁtting the model [66], by estimating the model parameters,
each case with the estimated class probability higher than 50%was
classiﬁed as having dyslipidemia, or normal otherwise. In fact, DT and
MLR could select relevant features because of the internal statistical
validation. For MLP and SVM, Sequential Forward Selection (SFS)
method, a bottom-up search procedure [67], was used for feature
selection.2.5. Validation
2.5.1. The performance indices for each classiﬁer
The performance of the classiﬁers was determined using the
holdout method, where the dataset was split into two mutually ex-
clusive sets (50% training and 50% test). The classiﬁers were then
trained on the training set and tested on the test set [68]. Moreover,
4-foldcross-validation (60% estimation, 15% validation, 25% test in
each analysis fold) was used to test the best classiﬁers to control a
possible biased error estimate [67]. A variety of performance indices
[15,69,70] were reported for the analyzed classiﬁers. Such indices
along with their deﬁnitions were shown in Table1, among which,
MCC is a single unbiased performance measure in balanced as well
as imbalanced datasets [71]. It is related to chi-square statistics,
also known as phi-coefﬁcient, a measure of association for two bi-
nary variables (predicted versus observed gold-standard class)
that could be interpreted as the correlation coefﬁcient between
those binary variables [72]. The interpretation of the reference in-
tervals of the indices AUC ROC [73], Kappa [74], MCC [75] and DP
[69,76] was listed in Supplementary material S3.
A diagnosis systemwas considered as clinically reliable based on its
Type I and II statistical errors [77], False Discovery Rate (FDR= 1-Preci-
sion) [78], and DOR [79] as to fulﬁll –all– the following conditions: the
minimum Sensitivity, Speciﬁcity, Precision and DOR of 80%, 95%, 95%
and 100, respectively.Table1
The classiﬁcation performance measures used in our study.
Se ¼ Rl ¼ TPTPþFN Sp ¼ TNTNþ
Pr ¼ TPTPþFP FA= α
F1S ¼ 2 PrRlPrþRl AUC ¼ S
LR− ¼ 1−SeSp DOR ¼ LL
MCC ¼ TPTN−FPFNﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃðTPþFPÞðTPþFNÞðTNþFPÞðTNþFNÞp Kappa =
True positive (TP): subjectswith dyslipidemia, correctly identiﬁed; false positiv
(TN): subjectswithout dyslipidemia, correctly identiﬁed; false negative (FN): s
Sp: speciﬁcity; FA: false alarm; Acc: accuracy; Pr: precision; F1S: F1-Score; AUC
hood ratio; DOR: diagnosis odds ratio; MCC: Matthews correlation coefﬁcient;
agreement rate between the predicted class labels and the gold standard.2.5.2. Comparison between different classiﬁers
When different classiﬁers are compared with the gold standard, the
superiority of one method to another must be presented using a proper
statistical test. Otherwise, insigniﬁcant improvements might be errone-
ously reported as important [70]. McNemar's test, also known as the
Gillick test, was used to compare the performance of two classiﬁers
[67,80].
2.6. Statistical analysis
Results are reported asmean± standard deviation (for interval var-
iables) and frequencies (for categorical variables).The pairwise χ2 anal-
ysis was used to test for allele frequency differences (and nominal
features) between dyslipidemia and normal groups and when the
Cochran conditions were not met, the Fisher exact test was used. The
χ2 analysis was used to test genotype frequency deviations from what
predicted by the Hardy Weinberg equation. P-values less than 0.05
were considered signiﬁcant. The entire data processing was performed
off-line using Matlab version 8.6 (The MathWorks Inc., Natick, MA,
USA). The statistical analysis and calculations were performed using
the SPSS statistical package, version 16.0 (SPSS Inc., Chicago, IL, USA).
3. Results
The average age of the participants was 14.66 ± 2.61 years. Among
the number of 725 patients participated in our study, 42.34% had dyslip-
idemia. Characteristics of the participants, grouped by their classiﬁca-
tion with/without dyslipidemia, are depicted in Table2. SNP genotype
and allele frequencies in the study population were shown in Table3.
None of the SNP distributions showed the deviation from Hardy-
Weinberg equilibrium. Moreover, nucleotide pairs (Table3) showed
better discrimination compared with carrier/non-carrier variables.
Thus, nucleotide pairs, were used for prediction.
Three feature subsets were considered for prediction. Set 1 included
sex, analyzed SNPs and family history of diseases: sex, LPL D9N
[rs1801177], ABCAI V771M [rs2066718], LPL LPL HindIII [rs320], LPL
S447X [rs328], ABCAI R1587K [rs2230808], CETP TaqIB [rs708272],
APOC3 SstI [rs5128], CETP A373P [rs5880], APOA1 MspI [rs2893157],
APOA5 C-1131T [rs662799], ApoE, Family history of diabetes, obesity,
cancer, and CVD. Set 2 included Set 1 and birth weight, age, and physical
activity. We also considered set 3 in which easily-measured features
were analyzed, i.e., sex, age, physical activity, birth weight, BMI category,
abdominal obesity, family history of diabetes, obesity, cancer, and CVD.
The hold-out (50%) validation of the proposed method as well as the
base learners DT, MLP, MLR, and SVM were performed in each feature
subset, and the results of the classiﬁers on the test set were shown in
Table4.
In each feature subset, the proposed method signiﬁcantly
outperformed the base learners (DT, MLP, MLR, and SVM) (P-value
b 0.05). In the third subset, the entire base learners did not reject
the NULL hypothesis of an accidental agreement. Moreover, in such
classiﬁers, the AUC ROC was not signiﬁcant (P-value b 0.05) showingFP Acc ¼ TPþTNTPþTNþFPþFN
= 1− Sp Power= 1− β= Se
eþSp
2
LRþ ¼ Se1−Sp
Rþ
R− DP ¼ ð
ﬃﬃ
3
π
q
Þ  logðDORÞ
agreement rate
e (FP): subjectswithout dyslipidemia, incorrectly identiﬁed; truenegative
ubjectswith dyslipidemia, incorrectly identiﬁed; Se: sensitivity; Rl: recall;
: area under the receiver operating characteristic (ROC) curve; LR: likeli-
DP: discriminant power; Kappa: Cohen's kappa coefﬁcient deﬁned as the
Table2
Characteristics of the participants in the dyslipidemia and normal groups.
Dyslipidemia⁎
Predictors Categories No Yes OR [CI 95%] P-value
Age (years) 14.28 ± 2.26 14.64 ± 2.39 – 0.058
Sex Male 49.28 46.61 0.90 [0.67,1.21] 0.477
Female –
Region Urban 64.80 71.71 1.38 [1.01,1.89] 0.049
Rural –
Family history of diabetes No 70.54 66.14 – 0.207
Yes 1.23 [0.89,1.68]
Family history of obesity No 68.32 70.12 – 0.604
Yes 0.92 [0.67,1.27]
Family history of cancer No 83.23 78.88 – 0.137
Yes 1.33[0.91,1.93]
Family history of CVD No 87.16 92.43 – 0.023
Yes 0.55 [0.33,0.93]
Abdominal obesity No 88.41 61.59 – b0.001
Yes 4.76 [3.26,6.94]
BMI category (WHO criteria) Under weight 25.85 19.52 0.76 [0.52,1.09] 0.007
Normal 58.22 58.17 -
Over weight 8.36 10.76 1.29 [0.77,2.15]
Obese 7.57 11.55 1.53 [0.91,2.56]
Physical activity Mild 25.47 45.82 2.03 [1.43,2.87] b0.001
Moderate 40.37 35.86 –
High 34.16 18.32 0.60 [0.40,0.89]
Birth weight Low 11.67 16.73 1.54 [1.0,2.34] 0.249
Normal 79.58 74.10 –
High 8.75 9.17 1.13 [0.67,1.89]
Systolic blood pressure (mm Hg) 101.87 ± 13.16 104.16 ± 13.09 – 0.025
Diastolic blood pressure (mm Hg) 65.89 ± 10.74 66.69 ± 10.61 – 0.338
Fast blood sugar (mg/dL) 87.6 ± 11.85 84.32 ± 11.85 – 0.002
HDL-C (mg/dL) 59.95 ± 18.22 29.40 ± 12.37 – b0.001
LDL-C (mg/dL) 75.43 ± 28.35 92.55 ± 38.09 – b0.001
Total cholesterol (mg/dL) 149.66 ± 29.50 154.46 ± 30.20 – 0.061
Triglyceride (mg/dL) 86.06 ± 33.08 93.35 ± 34.35 – b0.001
*: Results are reported asmean± standard deviation (for interval variables) and percentage (for categorical variables). CVD: cardio-vascular disease; BMI: bodymass index;WHO:world
health organization; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol; OR: Odds ratio (a categorical level was set to reference for each categorical
variable); CI: conﬁdence interval. In each dyslipidemia group, the frequency percentage of one of the categories in binary variables was shown.
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proposed classiﬁer on the set 2 signiﬁcantly outperformed than sets
1 and 3 (P-value b 0.05). Also, the results of Set 1 was signiﬁcantly
better than those of Set 3 (P-value b 0.05).
The selected features of the proposed classiﬁer on the Set 1were CETP
TaqIB [rs708272], CETP A373P [rs5880], LPL D9N [rs1801177], ApoE,
ABCAI R1587K [rs2230808], APOA5 C-1131T [rs662799], LPL HindIII
[rs320], APOC3 SstI [rs5128], family history of obesity, and diabetes, and
APOA1 MspI [rs2893157]. Such features for Set 2 were CETP TaqIB
[rs708272], ApoE, LPL D9N [rs1801177], ABCAI R1587K [rs2230808],
age, birth weight, family history of obesity and for Set 3 were abdominal
obesity, birthweight, physical activity, family history of diabetes, and BMI
category. The performance of the best classiﬁers in each subset (i.e. the
proposed classiﬁer) was further assessed using 4-fold cross validation
(Table5).
The proposed prediction system showed limited discriminant power
(DP= 1.3), excellent diagnosis accuracy (AUC ROC= 0.94), excellent
agreement with the gold standard (Kappa= 0.87) and high correlation
with the gold standard (MCC=0.87) on the second subset (Table4). The
average statistical power and Type I error (α) were 93 % and 0.07, re-
spectively based on the cross-validation on the second subset
(Table5). The training time of the proposed system was 26.1 ± 2.2 (s),
33.6 ± 3.0 (s) and 20.5 ± 3.1 (s)in the ﬁrst, second, and third subsets,
respectively. The average running time was the average of 3 runs over
363 subjects in the training set (hold-out 50%) on an Intel Core i7-
6500uCPU with 8 GB of RAM.
4. Discussion
Identifying high-risk children based on gene polymorphisms (sets 1,
and 2), at the ﬁrst place, is useful for further dietary, and life-styletreatments and screening. Using life-style, anthropometric indica-
tors and family history of diseases (set 3), on the other hand, could iden-
tify the high-risk population in low-income countries.
4.1. The risk factors of dyslipidemia
Although the environment is very important in the development
of dyslipidemia, genetic components are also critical [81]. CETP
TaqIB [rs708272] was selected by the proposed dyslipidemia predic-
tion system in both sets 1 and 2. In the literature, Genome wide asso-
ciation studies (GWAS) in adults showed a high correlation between
CETP and plasma lipid concentrations [82]. However, such an associa-
tion is less distinct in children [33,83]. It was shown in the literature
that such a mutation has the protective effect on dyslipidemia [33]
and Myocardial Infarction (MI) [84]. This was in agreement with
our ﬁndings, where the OR of CT/TT vs. CC was 0.15 (P-valueb0.001)
(Table3).
ApoE was also selected in both sets. ApoE, playing an important
function in lipid metabolism, has three isoforms, Apo-e2, Apo-e3, and
Apo-e4. They are in fact translated into three alleles of the gene. It was
shown in the literature that ApoE , and particularly, its e4 isoform, is
associated with plasma lipid parameters and CVD risks [85,86].
Similarly, in our study, the prevalence of dyslipidemia was 85% in
subjects with ApoE-e4 isoforms. Moreover, the OR of e2/e4 vs. e3 was
1.73 (P-value b 0.001) (Table3).
ABCAI R1587K [rs2230808] was the other selected feature in both
sets 1 and 2. Several ABCA1 gene polymorphisms including R1587K
[rs2230808], were identiﬁed. Dean et al. showed that this SNP is associ-
ated with the HDL-C concentration [87], thus affecting dyslipidemia. In
our study, the OR of AG/GG vs. AA was 2.21 (P-value b 0.001) (Table3).
Thus, such polymorphisms increased the risk of dyslipidemia.
Table3
SNP genotype and allele frequencies (in percentage) of the participants in the dyslipidemia and normal groups.
Polymorphism Genotype and allele⁎ Dyslipidemia OR [CI 95%] P-value
No Yes
LPL D9N [rs1801177] AA 96.4 91.2 – 0.003
AG 2.59 [1.35–4.96]
ABCAI V771M [rs2066718] GG 94.0 98.7 - 0.002
GA 0.21 [0.07–0.60]
LPL HindIII [rs320] GG 24.4 50.8 – b0.001
GT 48.6 42.0 0.31 [0.23–0.43]
TT 27.0 7.2
LPL S447X [rs328] CC 72.7 88.6 – b0.001
CG 24.6 10.4 0.34 [0.23–0.52]
GG 2.6 1.0
ABCAI R1587K [rs2230808] AA 66.7 47.6 – b0.001
AG 29.9 39.4 2.21 [1.64–3.00]
GG 3.3 13.0
CETP TaqIB [rs708272] CC 19.1 60.6 – b0.001
CT 61.7 35.5 0.15 [0.11–0.22]
TT 19.1 3.9
APOC3 SstI [rs5128] CC 83.0 83.7 – 0.371
CG 16.7 15.3 0.95 [0.64–1.41]
GG 0.2 1.0
CETP A373P [rs5880] CC 93.5 77.9 – b0.001
CG 6.5 20.8 4.12 [2.56–6.62]
GG 0.0 1.3
APOA1 MspI [rs2893157] GG 69.4 74.3 – 0.119
GA 27.8 24.8 0.79 [0.56–1.09]
AA 2.9 1.0
APOA5 C-1131T [rs662799] CC 98.8 97.7 – 0.525
CT 0.5 1.0 1.93 [0.61–6.13]
TT 0.7 1.3
ApoE e2 6.9 0.7 1.73 [1.08–2.76] b0.001
e4 1.7 13.4
e3 91.4 86.0 –
*: The allelesGG (SNP rs1801177) andCC (SNP rs2066718) had zero frequency inbothnormal anddyslipidemia groups and thus not shown in the results. OR:Odds ratio (a categorical levelwas
set to reference for each categorical variable); CI: conﬁdence interval. In each dyslipidemia group, the frequency percentage of one of the categories in binary variables was shown.
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Corsetti et al. showed that D9N is as a predictor of CVD risk directly and
through its interaction with TaqIB [30]. In fact, LPL is involved with
triglyceride-rich lipoprotein metabolism and lipoprotein remodeling in-
cluding HDL [88,89]. Similarly in our study, the OR of (AG/GG vs. AAwas
2.59 (P-value= 0.003) (Table3).
The family history of obesity was another common feature. Valdez et
al. indicated that peoplewho have one ormore relativeswith diabetes or
CVD have a high risk of such problems [90]. Such diseases have common
risk factors such as obesity and dyslipidemia sharing etiology [91]. FH of
obesity, however, had poor agreement ratewith FH of diabetes in our da-
tabase (Cohen's Kappa = 0.24; P-value b 0.05). FH of diabetes was se-
lected in the ﬁrst and third subset, though. The prevalence of
dyslipidemia in subjects without FH of obesity and diabetes were 43%
and 41%, respectively.
Birth weight was a selected feature for the subsets 2 and 3.
Rodríguez Vargas et al. showed that high birthweight is not a risk factor
for hypercholesterolemia or HDL and LDL-cholesterol esters, but is
positive for TG [92]. In our study the ORs of the low and high birth
weight categories were more than one, but not signiﬁcant (Table3).
The prevalence of dyslipidemia in the abnormal and normal birth
weight groups were 45% and 41%, respectively.
CETP A373P [rs5880] was selected in the ﬁrst set. Agerholm-Larsen
et al. indicated that such a polymorphism is associated with decreased
HDL-C [93]. Heidari-Beni et al. showed that HDL-C levels were signiﬁ-
cantly lower among those with CETP A373P [rs5880] polymorphism
[33]. In our study, the OR of CG/GG vs. CC was 4.12 (P-value b 0.001)
(Table3).
APOA5 C-1131T [rs662799] was another selected SNP in the ﬁrst set.
Wang et al. indicated that this polymorphism is associated with dyslip-
idemia and the severity of CHD [94]. In our dataset, the OR of AG/GG vs.AA was 1.93, but it was not signiﬁcant due to the small sample size of
carrier genotypes (P-value= 0.525) (Table3).
Radha et al. found an association between LPL HindIII [rs320] SNP
with lowHDL-C and elevated TG levels [95]. Song et al. indicated a signif-
icant association between the APOC3 SstI [rs5128] polymorphism and
higher levels of TG, TC, and LDL-C [35]. Albahrani et al. showed that
APOA1 MspI [rs2893157] polymorphism is associated with CVD risk
[36]. We did not ﬁnd such an increased risk of dyslipidemia for LPL
HindIII [rs320], APOC3 SstI [rs5128] and APOA1 MspI [rs2893157]
SNPs. However, Odds (dyslipidemia| GG) was 1.5 in LPL HindIII [rs320]
showing that this was possibly a good feature for the proposed classiﬁer.
Due to the small sample size of AA alleles in APOA1 MspI [rs2893157]
and GG alleles in APOC3 SstI [rs5128] (Table3), no signiﬁcant association
between such polymorphisms and the risk of dyslipidemia was found.
Anthropometric indices such as BMI and WHtR were shown to be
associated with dyslipidemia in children and adolescents in the litera-
ture [96]. In our study, people with abdominal obesity had 4.76 times
risk of dyslipidemia (OR = 4.76; P-value b 0.001) compared with
those without such an obesity (Table2). Moreover, overweight and
obese subjects had a higher risk of dyslipidemia compared with normal
BMI subjects (Table2). In fact, WHtR and BMI were moderately corre-
lated (r = 0.737; P-value b 0.001). WHtR was poorly correlated with
TG (r = 0.257; P-value b 0.001) while BMI was poorly correlated with
SBP (r = 0.248; P-value b 0.001) and TG (r (Pearson's correlation) =
0.293; P-value b 0.001). They could be the reason why BMI and WHtR
were selected by the proposed classiﬁer on the third set.
Panagiotakos et al. showed that lipid proﬁle disorders are corre-
lated with physical activity [97]. In our dataset, the ORs of high and
low physical activity compared with moderate activity were 0.60
(P-value b 0.001) and 2.03 (P-value b 0.001), respectively (Table2). It
was poorly correlated with HDL levels (ρ (Spearman's correlation)
Table4
The hold-out (50%) validation of the classiﬁers.
Feature subset Classiﬁer Se
%
Sp
%
Acc
%
F1S
%
Pr
%
FA AUC MCC DOR DP Kappa
1 Proposed 85 91 88 86 87 0.09 0.88 0.76 57 1.0 0.76
DT 69 80 75 70 72 0.20 0.75 0.47 9 0.5 0.46
MLP 67 88 79 73 80 0.12 0.78 0.56 15 0.6 0.56
MLR 61 86 75 68 76 0.14 0.74 0.49 10 0.5 0.49
SVM 71 78 75 70 70 0.22 0.75 0.45 9 0.5 0.44
2 Proposed 93 95 94 93 93 0.05 0.94 0.87 252 1.3 0.87
DT 71 81 77 72 73 0.19 0.76 0.50 10 0.6 0.50
MLP 70 86 79 74 79 0.14 0.78 0.57 14 0.6 0.57
MLR 59 87 75 67 77 0.13 0.73 0.48 10 0.5 0.47
SVM 71 82 77 72 74 0.18 0.77 0.52 11 0.6 0.52
3 Proposed 82 84 83 80 79 0.16 0.83 0.64 24 0.8 0.64
DT 48 68 60 50 52 0.32 0.58⁎ 0.12 2 0.2 0.10⁎
MLP 17 93 61 27 64 0.07 0.55⁎ 0.16 3 0.2 0.13⁎
MLR 17 94 61 27 68 0.06 0.56⁎ 0.18 3 0.3 0.14⁎
SVM 61 68 65 59 58 0.32 0.65⁎ 0.17 3 0.3 0.12⁎
Set 1 included sex, analyzed SNPs and family history of diseases: sex, LPL D9N [rs1801177], ABCAI V771M [rs2066718], LPL HindIII [rs320], LPL S447X [rs328], ABCAI R1587K [rs2230808],
CETP TaqIB [rs708272], APOC3 SstI [rs5128], CETP A373P [rs5880], APOA1MspI [rs2893157], APOA5 C-1131T [rs662799], ApoE, Family history of diabetes, obesity, cancer, and CVD. Set 2
included Set 1 and birth weight, age, and physical activity. Set 3 included sex, age, physical activity, birth weight, BMI category, abdominal obesity, family history of diabetes, obesity, can-
cer, and CVD. The classiﬁers were trained on the same training set and then validated on the test set and the results of the classiﬁers on the test set were shown.
⁎ Non-signiﬁcant (P-value N 0.05).
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third set. Age was selected in the second set. Age was shown to be
an independent predictor of dyslipidemia in children and adolescents
[26]. Although age was directly used in the second set, age and sex
are indirectly required for dyslipidemia prediction on the thirst set.
The identiﬁcation of BMI category in children and adolescents is de-
pendent on the growth-curve charts that are gender and age speciﬁc
[45].
4.2. Application in health policy making
The proposed automatic diagnosis of dyslipidemia on the third set
is indeed an effective screening system. It used the input features of
abdominal obesity, birth weight, physical activity, family history of
diabetes, and BMI category. It includes therapeutic life-style change
(e.g., dietary therapy, and increased physical activity), before necessary
pharmacologic interventions [98]. In fact, the primary treatment for
dyslipidemia in children and adolescents is such a life-style change
[26].
Although the proposed system on the set 3 it is not a fully clinically
reliable system (Type I error of 16% and FDR of 21%), it could be possibly
used in low- and middle- income countries where genomics is not
possible for a large population. Moreover, embedding the prediction
system into a public online web-interface is useful in health promotion
programs [15,99] that will be the focus in our future work.
4.3. The Properties and Performance of the proposed system
The proposed system for dyslipidemia prediction in the subset 2,
showed promising results regarding variety of performance indices
(Tables4 and 5). The statistical power, Type I error, FDR and DOR of
the proposed system were 93%, 0.05, 7%, 252 (Table4). Thus, the pro-
posed system fulﬁlled the criteria of a clinically reliable system exceptTable5
The four-fold cross validation results of the proposed prediction system in MEAN± SD.
Feature subset Se
%
Sp
%
Acc
%
Pr
%
1 87± 2 90 ± 1 89 ± 1 86 ± 1
2 93± 2 94 ± 1 94 ± 1 92 ± 1
3 83± 2 84 ± 2 84 ± 1 79 ± 2
Se: sensitivity; Sp: speciﬁcity; Acc: accuracy; Pr: precision.that it surpassed theminimumrequired FDRof 5% by 2%.We considered
a variety of performance indices introduced in the literature (Tables1
and 2), and also the Standards for Reporting Diagnostic Accuracy
(STARD 2015) and its extensions [70,100] in reporting the results.
Guarding against testing hypotheses suggested by the data (Type III er-
rors [101]) done by cross-validation and the low variation (high
consistency) of the performance indices in different folds (Table5),
excellent balanced diagnosis accuracy (AUC ROC = 0.94), excellent
class labeling agreement rate (Kappa= 0.87), high correlation between
predicted and observed class labels (MCC= 0.87), limited discriminant
power (DP= 1.3) (Tables2 and 4), it is promising for clinical diagnosis
tests. It signiﬁcantly outperformed the other systems namely as DT,
MLP, MLR, and SVM (McNemar's test; P-valueb0.05).
Selecting only one kind of lipid disorder such as high total
cholesterol/HDL-C ratio rather than dyslipidemia, could facilitate the
interpretation of the results [20]. However, dyslipidemia contributes
to cardio-metabolic risks in children and adolescents [102]. Moreover,
In addition to cholesterol and HDL-C [103], triglyceride [104] and LDL-
C [105]were shown to be important CVD risk factors. Thus, the outcome
of the proposed systemwas dyslipidemia.We also considered high total
cholesterol/HDL-C ratio outcome in our study and the selected features
in the feature set 1 were ABCA1 (R1587K [rs2230808]), CETP (A373P
[rs5880]), LPL (HindIII [rs320]), LPL (D9N [rs1801177]), and CETP
(TaqIB [rs708272]). The AUC of this model was 0.82 in the hold-out
validation.
4.4. Further application of the proposed classiﬁcation system
The proposed dyslipidemia prediction system made use of the
following properties: I) mapping the mixed-data types to interval data
using Logit function, II) RELIEF feature selection, III) PSS random
sampling for imbalanced datasets, IV) the involvement of feature
interactions proposed by GMDH, V) using the nonlinear regression ma-
trix instead of a ﬁxed regression polynomial, VI) using inner-loopRLS in-
stead of LS, VII) using outer-loopPSO for stochastic optimization, VIII)
using estimation, validation and test sets to avoid over-ﬁtting, IX) inter-
nal cross validation on the training set (estimation plus validation set)
to improve generalization capability, and X) proper cost function as
the mean of Se, Sp, and Pr suitable for imbalanced data sets.
In fact, the proposed system could be regarded as a general frame-
work for two-class classiﬁcation of imbalanced mixed-type data given
that it is successfully tested on different datasets. The following datasets
were used for validation of the proposed framework: Wisconsin breast
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[107]. The performance of the proposed framework on such datasets
was shown in Supplementary material S4.
4.5. Final considerations
The limitation of the current study is that it was a retrospective
study. More sources of error are more common in such studies
compared with prospective studies because of bias and possible con-
founders [108]. Also, the sample size must be increased as to improve
the statistical power in our diagnosis system [109]. Moreover, instead
of testing a small number of pre-speciﬁed genetic regions, performing
GWAS could be used in the examination of a genome-wide set of ge-
netic variants in the entire genome in different individuals. For instance,
more-prevalentmutations in LDL receptor (LDLR) genewere associated
with dyslipidemia such as familial hypercholesterolemia, which is
associated with early severe atherosclerosis and CAD [110]. In our
study, NHLBI guideline was used to deﬁne dyslipidemia in children
and adolescents. However, other standards such as American Heart
Association (AHA) guideline [111] exist. The AHA guideline has
different cut-points for TG and HDL-C. It also does not have a non-
HDL-C criterion. Using AHA guideline, the class labels might change;
thus affecting the proposed classiﬁcation system. Finally, external
validation (i.e. assessing the performance of the model on datasets
from different institutions) is required in addition to an internal valida-
tion (i.e. hold-out and cross-validation) [112]. Unlike Costanza and
Paccaud who rightfully used external validation in assessing their
proposed lipid-disorder prediction model [20], other studies such as
Wang et al. [19] and our study in this ﬁeld and many studies in the
other data mining areas in the literature do have only traditional inter-
nal cross-validation. This is the other limitation of our study.
5. Conclusions
In conclusion, we proposed a computer-aided diagnosis system to
predict dyslipidemia whose performance was assessed using different
criteria and in different validation frameworks. It is accurate and precise
and could be possibly used for screening and risk assessment in the
health promotion programs for children and adolescents. The devel-
oped framework is available to interested readers upon request.
Supplementary data to this article can be found online at https://doi.
org/10.1016/j.csbj.2018.02.009.
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